ERBB2 and neoplasm: Furthermore, Wang et al. proved the successful development of a novel delivery carrier, GO-R8/anti-HER2 (GRH), through conjugating R8 and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin–siRNA delivery [74].